Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Current Liabilities (2017 - 2025)

Crinetics Pharmaceuticals has reported Total Current Liabilities over the past 9 years, most recently at $85.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $85.1 million for Q4 2025, up 42.54% from a year ago — trailing twelve months through Dec 2025 was $85.1 million (up 42.54% YoY), and the annual figure for FY2025 was $85.1 million, up 42.54%.
  • Total Current Liabilities for Q4 2025 was $85.1 million at Crinetics Pharmaceuticals, up from $74.2 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CRNX hit a ceiling of $85.1 million in Q4 2025 and a floor of $10.3 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $36.5 million (2023), compared with a mean of $39.8 million.
  • Biggest five-year swings in Total Current Liabilities: decreased 4.61% in 2021 and later surged 119.1% in 2022.
  • Crinetics Pharmaceuticals' Total Current Liabilities stood at $16.0 million in 2021, then skyrocketed by 73.32% to $27.7 million in 2022, then surged by 58.5% to $43.9 million in 2023, then skyrocketed by 35.82% to $59.7 million in 2024, then surged by 42.54% to $85.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $85.1 million (Q4 2025), $74.2 million (Q3 2025), and $68.4 million (Q2 2025) per Business Quant data.